特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

市場アクセスにおける課題:腎細胞癌 (EU5カ国)

Market Access Impact: Renal Cell Carcinoma (EU5) 2018

発行 FirstWord 商品コード 509315
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
詳細については [見積・お問合せ] ボタンよりお問い合わせ下さい。
市場アクセスにおける課題:腎細胞癌 (EU5カ国) Market Access Impact: Renal Cell Carcinoma (EU5) 2018
出版日: 2018年04月01日 ページ情報: 英文
概要

当レポートでは、EU5カ国 (フランス・イタリア・ドイツ・スペイン・英国) の癌専門医150名を対象に腎細胞癌治療薬の処方動向を調査し、市場アクセスにおける各種障壁と処方への影響、主要9ブランド薬の処方に関する比較分析・個別分析を行っています。

調査対象

  • Afinitor (エベロリムス:Novartis)
  • Avastin (ベバシズマブ:Roche)
  • Cabometyx (カボザンチニブ:Exelixis/Ipsen)
  • Inlyta (アキシチニブ:Pfizer)
  • Kisplyx (レンバチニブ:エーザイ)
  • Nexavar (ソラフェニブ:Bayer)
  • Opdivo (ニボルマブ:Bristol-Myers Squibb)
  • Sutent (スニチニブ:Pfizer)
  • Torisel (テムシロリムス:Pfizer)
  • Votrient (パゾパニブ:Novartis)

調査課題

  • 各種障壁の市場アクセスへの影響
    • 医師がもっとも多く処方するブランドは?
    • 市場の障壁は処方の意思決定にどのように影響しているか?
    • 各種障壁に影響力の違いはあるか?
  • 各ブランドへの障壁の影響
    • 各ブランドを処方する医師の数は?処方していないが検討するつもりの数は?
    • 処方しない理由は?その代わりに処方しているものは?
    • 市場シェアを取り合っている競合ブランドは?
目次

Market barriers affect 14 percent of RCC prescriptions in Europe. Is your brand losing out?

Despite market barriers only affecting 14 percent of all renal cell carcinoma (RCC) prescriptions in Europe, certain brands are losing on market share. Is it yours? Find out what's driving share gains, and what your brand can do to level the playing field in Market Access Impact: RCC (EU5) [2018]. Based on a survey of 150 medical oncologists, the report covers 10 major therapies from Novartis, Roche, Ipsen, Pfizer, Exelixis, Amgen, Bayer, and BMS. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Barriers affect 14 percent of all prescriptions. Small, perhaps, but brands are still losing out on market share opportunities because of them. Is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • Four brands see robust share increases. Is this lead too big for the chasing pack to overcome? Is your brand leading, or are you in the chasing pack?
  • One brand sees a significant loss. Perhaps due to limited prescribing, but other issues could be at play. What are these issues, and what can be done about them?
  • Eliminating barriers would close the gap mid-table. Due to the overall barrier impact being below 10 percent, changes at the top and bottom of the table won't be seen if barriers are eliminated; not so mid-table, where changes would be seen.
  • Perception is not the problem. But perhaps a willingness to use is? Between 17-21 percent of physicians would not consider using 3 brands? Is your brand in the mix?

Insight into 10 Major RCC Treatments

  • Afinitor (everolimus; Novartis)
  • Avastin (bevacizumab; Roche)
  • Cabometyx (cabozantinib; Exelixis/Ipsen)
  • Inlyta (axitinib; Pfizer)
  • Kisplyx (lenvatinib; Eisai)
  • Nexavar (sorafenib; Bayer)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Sutent (sunitinib; Pfizer)
  • Torisel (temsirolimus; Pfizer)
  • Votrient (pazopanib; Novartis)

Exploring Important Market Access Issues

Market Access Impact: Renal Cell Carcinoma (EU5) explores key issues affecting RCC drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

Table of Contents

1.What are market barriers?

2.About this report

3.About the survey

4.Brands included in the survey

5.Executive summary